Skip to content
StockMarketAgent
Direct answer
NTES trades against a final fair-value range of $139.31-$218.83, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $139, high $219, with mid-point at $178.
Stock analysis

NTES fair value $139–$219

By StockMarketAgent.AI team· supervised by
Przeanalizowano: 2026-05-20Następna aktualizacja: 2026-08-20Methodology v2.4Data cut-off: Quality gate: passSources: all material sources passed deterministic freshness/provenance gatesReview: automatedArchetype: Mature compounder
View archive
Cena
$114.49
▲ +63.29 (+55.28%)
Wartość godziwa
$178
$139–$219
Rekomendacja
Zdecydowanie kupuj
confidence 82/100
Potencjał wzrostu
+55.3%
upside to fair value
Margines Bezpieczeństwa
$151.11
MoS level · 15%
Kapitalizacja
$73.4B
P/E fwd 11.2
Awaryjny angielskiPL
Pokazujemy źródło angielskie podczas tłumaczenia
Ten raport nie został jeszcze przetłumaczony. Odśwież za kilka minut, gdy kolejka tłumaczeń go przetworzy.

§1 Podsumowanie wykonawcze

  • Composite fair value $178 with high case $219.
  • Implied upside of 55.3% to fair value.
  • Moat 8/10 · confidence 82/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$178
Margin of safety
+35.6%
Confidence
82/100
Moat
8/10

Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.

$114.49Price
Low $139.31
Mid $177.78
High $218.83

NTES trades against a final fair-value range of $139.31-$218.83, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Proprietary IP portfolio with 15+
    Proprietary IP portfolio with 15+ year lifecycle duration
  • Massive R&D scale supporting high-fidelity
    Massive R&D scale supporting high-fidelity production
  • Bull thesis
    Value: Trading at 11.2x fwd P/E vs 20x global peers

§2 Scenariusz negatywny

A bear-case stress test assuming a 500bps margin compression and 0% terminal growthTerminal growthThe perpetual growth rate assumed in the Gordon-growth terminal-value calculation. Capped below long-run nominal GDP (typically 2.5–3.0% for developed-market firms). resets fair valueFair valueOur composite estimate of intrinsic per-share value, blended across DCF, exit-multiple, and reverse-DCF methods. Reported as a low/mid/high range to capture model uncertainty. to $139.31. Even in this high-pessimism scenario, the massive net cash position ($40B+) provides a structural floor representing 55% of the current market capitalization.

Jak ta teza może się załamać

Regulatory Monetization Freeze

15%· Low

China introduces draconian caps on daily spending and loot box mechanics for legacy titles.

FV impact
40% decline
Trigger
6-12 months

Global Pipeline Failure

25%· Medium

High-budget international launches (Where Winds Meet) fail to gain traction, rendering global R&D sunk costs.

FV impact
15% decline
Trigger
18-24 months

Cash Seizure/Restricted Access

10%· Low

Geopolitical escalation leads to restrictions on offshore cash transfers or ADR de-listing.

FV impact
50% decline
Trigger
Immediate
Sygnały wczesnego ostrzegania do monitorowania
WskaźnikBieżącyPróg wyzwalania
Sustained quarterly ARPU decline in legacy titlesMonitorDeterioration versus the report thesis
Delay or cancellation of key 2026/27 global releasesMonitorDeterioration versus the report thesis
Reduction or suspension of established buyback programsMonitorDeterioration versus the report thesis
Operating margin compression below 28% thresholdMonitorDeterioration versus the report thesis
Resumption of aggressive regulatory finesMonitorDeterioration versus the report thesis

§3 Historia finansowa

Rachunek zysków i strat — ostatnich sześć okresów
PozycjaT−0T−1T−2T−3CAGR
Okres2022-12-312023-12-312024-12-312025-12-31Trend
Przychody$96.50B$103.47B$105.30B$112.63B+5.3%
Zysk brutto$52.77B$63.06B$65.81B$72.40B+11.1%
Zysk operacyjny$19.63B$27.71B$29.58B$35.83B+22.2%
Zysk netto$20.34B$29.42B$29.70B$33.76B+18.4%
EPS (rozwodniony)$30.85$45.25$45.95$52.40+19.3%
EBITDA$22.49B$30.76B$32.00B$38.08B+19.2%
R&D$15.04B$16.48B$17.52B$17.72B+5.6%
SG&A$18.10B$18.87B$18.70B$18.85B+1.4%

Wyniki jakości

OCF / Zysk netto
1.5×
>1 wskazuje wysoką jakość wyników
Bramka jakości księgowej
Fail
Bramka skorygowana o sektor
ROIC
17.0%
Zwrot z zainwestowanego kapitału
Sekcja 3

Numbers analysis

Przepływy pieniężne

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Alokacja kapitału

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Subskrybenci indywidualni — od §411 kolejnych sekcji

Przeczytaj pełną analizę — 11 kolejnych sekcji.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Pełny raport dla każdego pokrytego tickera
24 miesiące archiwum rekomendacji
Briefingi watchlisty + alerty zmian rekomendacji
Eksport PDF + DOCX w dowolnym języku
Rozpocznij darmowy okres próbny
Anuluj w dowolnym momencie.
FAQ

NTES — frequently asked questions

  1. Based on our latest analysis, NTES looks meaningfully undervalued. The current price is $114 versus a composite fair-value midpoint of $178 (range $139–$219), which implies roughly 55.3% upside to the midpoint.
Related coverage

Names readers of NTES also follow

Same archetype: mature-compounder